NextPlat Corp reports developments across a healthcare and e-commerce business that provides healthcare and technology solutions through retail and online channels. Recurring news includes financial results, margin and expense updates, 340B covered-entity activity, contracted healthcare services, and prescription fulfillment through its PharmcoRx subsidiary.
Company updates also cover e-commerce and communications products, including voice, data, tracking, and satellite-enabled IoT offerings through Global Telesat Communications. Other recurring themes include AI-enabled pharmacy processing tools, customer and contract activity, Nasdaq listing compliance, and capital-structure actions such as share adjustments and warrant-related disclosures.
NextPlat (NASDAQ: NXPL) narrowed its third-quarter 2026 net loss attributable to common stockholders to $748,000 as healthcare margins improved. Revenue fell to $10.499 million from $13.752 million a year earlier, while gross profit rose to $3.678 million from $2.730 million. Consolidated gross margin reached approximately 35.0%, versus 19.9%. Diluted loss per share narrowed to $0.28 from $0.84.
Pharmacy contract revenue increased 300% to approximately $2.4 million, while prescription revenue fell to approximately $4.3 million from $9.5 million. E-commerce revenue increased 3% to approximately $3.8 million. Cash ended September at $11.220 million, down from $13.709 million at year-end. NextPlat completed the Scott's pharmacy acquisition after quarter-end and announced a Jacksonville opening. The company expects retail prescription volumes to increase starting in the fourth quarter and plans a nationwide medication fulfillment website launch that quarter.
NextPlat (NASDAQ: NXPL) will release its third-quarter 2026 financial results on November 12, 2026, followed by an investor conference call. The results cover the quarter ended September 30, 2026. Management will discuss the results and recent developments at 8:30 a.m. Eastern. A call replay will be available after 12:00 p.m. Eastern through November 26, 2026.
NextPlat (NXPL) plans to introduce automated prescription dispensing through its PharmcoRx subsidiary at select customer clinics and facilities using VendRx kiosks. Initial deployments are planned for later in the fourth quarter of 2026, with a wider rollout expected throughout 2027.
The kiosks will be installed at healthcare providers’ locations as part of PharmcoRx’s contracted pharmacy services. Patients will be able to collect prescriptions onsite after appointments and consultation with a PharmcoRx pharmacist.
NextPlat (NASDAQ: NXPL) has opened a PharmcoRx community pharmacy in Jacksonville, Florida, expanding its healthcare services network in the state.
The pharmacy is across from HCA Florida Memorial Hospital. Its planned services include prescription fulfillment, medication management and specialty pharmacy support for patients receiving complex or high-cost therapies. It will also offer contracted services for providers participating in the 340B discounted drug pricing program and services for long-term care facilities. PharmcoRx currently operates six retail pharmacies across Florida.
NextPlat (NXPL) completed the acquisition of an independent pharmacy near Pensacola, Florida, for total cash consideration of $1,485,439.
The purchase includes the pharmacy and its inventory. For the year ended December 31, 2025, the pharmacy generated approximately $5.6 million in sales. It was profitable, maintained positive working capital and operated with a debt-free balance sheet. NextPlat expects the pharmacy to contribute to growth and profitability in its PharmcoRx healthcare segment throughout the fourth quarter.
Integration into the PharmcoRx network is underway. NextPlat plans to introduce higher-margin contracted services for 340B, long-term care and senior living providers to enhance the pharmacy's profitability. The company is also exploring acquisitions of other established, profitable community operators. PharmcoRx currently operates five pharmacies across Florida.
NextPlat (NXPL) announced that its UK subsidiary Global Telesat Communications (GTC) has secured an agreement to sell satellite-enabled devices and connectivity products on Decathlon’s global digital e-commerce platform.
GTC will offer a broad range of products operating on satellite networks including Globalstar, Iridium and Inmarsat through Decathlon’s online marketplaces in 20 countries, opening a new consumer sales channel to Decathlon’s sports and outdoor customer base. Decathlon operates more than 1,700 stores in over 70 countries and regions. GTC plans to list communications, navigation, tracking and emergency-safety products tailored for outdoor activities in remote areas lacking reliable mobile coverage.
NextPlat (NASDAQ:NXPL) reported second quarter 2026 revenue of approximately $11.9 million, up about 21% sequentially from $9.9 million, driven by growth in contracted healthcare services and e-commerce. Overall gross margin reached a record ~40%, up from 35% in Q1 2026 and 22% a year earlier.
Contracted pharmacy revenue rose 136% year-over-year to about $2.2 million, while e-commerce revenue increased ~27% sequentially to $4.1 million. Net loss attributable to common stockholders narrowed to roughly $144,000, or ($0.05) per share, a 92% improvement from the prior-year quarter. The company ended June 30, 2026 with approximately $11.9 million in cash, working capital of about $14.2 million, and total liabilities of roughly $12.2 million.
NextPlat (NASDAQ: NXPL) will release its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026. Management will host a conference call that day at 8:30 a.m. Eastern to discuss the results and other recent developments, with live webcast and replay access provided.
NextPlat (NASDAQ: NXPL) issued a mid-year 2026 shareholder update highlighting completion of its strategic turnaround and a focus on achieving profitability. The company reported record consolidated gross margins of 35% for the quarter ended March 31, 2026, supported by rapid growth and margin expansion in its Healthcare Operations segment, which achieved a 39% gross margin, nearly double the prior-year level.
According to NextPlat, higher-margin 340B prescriptions rose over 70% year over year early in Q2 2026, with a record six new 340B contracts added in the quarter after five in Q1. The company cited a strong balance sheet with positive working capital, no material long-term debt, and over $11 million in cash as of March 31, 2026. New government-sector e-commerce sales surpassed $1.75 million in the first half of 2026.
NextPlat completed the strategic acquisition of an independent pharmacy near Pensacola, Florida, which it expects to provide profitable revenue and access to an underserved market. The company is preparing to launch a nationwide healthcare e-commerce site in Q3 2026 to sell prescription medications and OTC products in all 50 U.S. states and reports obtaining NABP Specialty Pharmacy Accreditation for its Pharmco unit. Management believes these initiatives position NextPlat to begin delivering quarterly operational profitability ahead of schedule and support growth into 2027.
NextPlat (NASDAQ:NXPL) announced that its PharmcoRx subsidiary has earned Specialty Pharmacy Accreditation from the National Association of Boards of Pharmacy (NABP). This voluntary accreditation recognizes advanced pharmacy services and disease management capabilities for medications requiring special handling, storage, and distribution.
According to NextPlat, PharmcoRx met comprehensive standards in patient management, quality management, and regulatory compliance. The company views this as a key milestone in its multi-year strategy to expand high-value pharmacy and specialty care services and strengthen relationships with large healthcare providers, payers, pharmaceutical manufacturers, and other institutional partners across the United States.